Drug shortage
Bupivacaine Hydrochloride Injection · Hospira, Inc., a Pfizer Company
FDA drug shortage · To Be Discontinued · updated Jan 10, 2025
Key facts
| Generic name | Bupivacaine Hydrochloride Injection |
|---|---|
| Proprietary name | Bupivacaine Hydrochloride |
| Company | Hospira, Inc., a Pfizer Company |
| Presentation | Bupivacaine Hydrochloride, Injection, 0.25%; 75 mg/30 mL (2.5 mg/mL); 30 mL Single Dose Glass Teartop Vial NOVAPLUS (NDC 0409-1159-10) |
| Dosage form | Injection |
| Strength | 0.25% 30 mL Single Dose Glass Teartop Vial NOVAPLUS 75 mg/30 mL (2.5 mg/mL) |
| Status | To Be Discontinued |
| Therapeutic category | Anesthesia |
| Package NDCs | 0409-1159-10 |
| First posted | Jan 10, 2025 |
| Last updated | Jan 10, 2025 |
| Discontinued | Jan 10, 2025 |
At a glance
- 1–9 Package NDCs affected
- 100–999 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: